Nexsen Lands HK$6M Hong Kong Grant to Fast-Track StrepSure Into Asian Hospitals
Nexsen secures HK$6 million Hong Kong government grant to accelerate StrepSure rollout
Nexsen has been awarded a HK$6 million (approximately A$1.2 million) IGNITE Grant from the Hong Kong Science and Technology Parks Corporation (HKSTP). The non-dilutive funding positions Hong Kong as a central manufacturing and distribution hub for the company’s StrepSure® point-of-care diagnostic as it executes its Asia-Pacific expansion strategy.
The grant brings Nexsen’s total non-dilutive funding to more than $13 million across its development programs, maintaining the company’s capital-efficient approach to milestone delivery without shareholder dilution.
Three key investment highlights underpin the funding award:
- Clinical validation: Immediate commencement of local validation studies for StrepSure® through established hospital networks
- Manufacturing hub: Establishment of Hong Kong-based production capability to support regional supply
- Hospital network access: Entry into a regional market of approximately 31,700 annual births with 21.5% GBS prevalence, within a broader Asia-Pacific birth cohort of 47 million annually
The HKSTP award validates Nexsen’s strategy to position Hong Kong as the operational centre for its Asia-Pacific rollout, providing government-backed support for both clinical and manufacturing execution.
When big ASX news breaks, our subscribers know first
What the IGNITE Grant funds and why it matters
The grant proceeds will be deployed across two parallel workstreams designed to advance StrepSure® towards commercial readiness in Asia-Pacific markets.
The first workstream focuses on clinical validation through hospital partnerships, generating real-world performance data needed to support regulatory pathways and early adoption. The second establishes manufacturing capability in Hong Kong to enable scalable production and regional supply reliability.
Both activities are structured to produce tangible commercial outputs rather than speculative development milestones. In-region manufacturing enables faster product iteration aligned with local clinical workflows, whilst validation studies through established hospital networks provide the performance data required for healthcare system integration.
| Grant Activity | Purpose | Commercial Benefit | Timeline Status |
|---|---|---|---|
| Clinical validation studies | Hospital partnerships | Real-world performance data | Immediate commencement |
| Manufacturing establishment | Scalable production | Regional supply capability | Grant-funded |
| Product optimisation | Asia-Pacific workflow alignment | Regulatory pathway support | Ongoing |
The grant also funds tailoring of device performance and design to meet specific clinical and workflow requirements of Asia-Pacific markets, supporting progression towards initial commercialisation in the region.
Managing Director Mark Muzzin emphasised the funding enables rapid execution on stated strategy:
Mark Muzzin, Managing Director
“The grant and support from the Hong Kong Government is strong validation of our strategy to position Hong Kong as a central hub for product manufacturing and distribution. It gives us the ability to move quickly on clinical validation and establish in-region manufacturing capability, bringing StrepSure® closer to commercial readiness and supporting early regional adoption across Asia-Pacific, which represents more than 33 million births annually, a significant addressable market for StrepSure®.”
What is the IGNITE Grant program
The IGNITE Grant is awarded by Hong Kong Science and Technology Parks Corporation, a government-backed organisation established to support innovation and technology development across strategic sectors including biotechnology and medical devices.
The program provides non-dilutive funding to companies advancing commercially viable technologies that align with Hong Kong’s strategic priorities. For Nexsen, the award represents external validation of both its technology platform and regional execution strategy.
Hong Kong operates a streamlined regulatory pathway for in vitro diagnostics (tests used to detect disease outside the body) through the Medical Device Administrative Control System (MDACS). This framework permits products to be approved based on local clinical validation, performance data and recognised quality standards, rather than requiring lengthy international approval transfers.
For companies seeking Asia-Pacific market entry, this pathway reduces regulatory complexity compared to other major markets whilst maintaining clinical and quality standards. The IGNITE Grant specifically funds the clinical validation activities required under this framework, connecting government support directly to regulatory progression.
Why Hong Kong anchors the Asia-Pacific opportunity
Hong Kong serves as a strategic launchpad rather than an isolated market, with regional dynamics supporting broader commercial expansion.
The regional opportunity is quantified by birth cohort data:
- Asia-Pacific: 47 million births annually
- Hong Kong regional market: Approximately 31,700 annual births
- Hong Kong GBS prevalence: Approximately 21.5%
- Asia-Pacific addressable market: More than 33 million births annually
Nexsen has established relationships with clinicians and healthcare networks across Hong Kong, providing a foundation for local validation, real-world data generation and early adoption. These partnerships are positioned to support efficient execution of the company’s clinical and commercial strategy.
The Hong Kong hub model enables proof-of-concept demonstration in a market with strong clinical infrastructure and regulatory clarity, before scaling to larger Asia-Pacific markets. Existing hospital relationships de-risk execution by providing established channels for validation studies and early-stage adoption.
The next major ASX story will hit our subscribers first
Management reinforces capital discipline and execution focus
Managing Director Mark Muzzin highlighted the company’s track record of securing non-dilutive funding whilst maintaining shareholder value:
Mark Muzzin, Managing Director
“Importantly for our shareholders, we continue to deliver against the milestones we’ve set out in a capital-efficient manner, without dilution.”
The HKSTP award builds on Nexsen’s established pattern of government-backed funding for product development and commercialisation. Total grant support across the company’s programs now exceeds approximately $13 million, demonstrating consistent access to non-dilutive capital sources.
This funding approach enables milestone delivery without equity dilution, maintaining the company’s capital structure whilst advancing towards commercial readiness. Australian manufacturing capacity supports initial production of up to 1 million devices per annum, complemented by the Hong Kong facility being established under the grant.
Next execution milestones supported by the IGNITE Grant include:
- Clinical validation initiation: Commencement of hospital-based validation studies
- Manufacturing establishment: Setup of Hong Kong production capability
- Product optimisation: Alignment with regional clinical workflows and regulatory requirements
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to get real-time alerts the moment market-moving announcements break across biotech, medtech and pharmaceuticals.